SNY catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
November 2026
- Primary completion Nov 25, 2026Sponsor estimatePhase 3NCT07216079Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in JapanSanofi · Immune ThrombocytopeniaActive, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 26, 2026Sponsor estimatePhase 4NCT07861542Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19Sanofi · COVID-19Active, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 28, 2026Sponsor estimatePhase 3NCT07103148A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric PopulationSanofi · Yellow Fever ImmunizationActive, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07457580Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)Sanofi · Type 1 DiabetesRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 1, 2026Sponsor estimatePhase 3NCT06838000Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy...Sanofi Pasteur, a Sanofi Company · Pneumococcal InfectionsActive, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 1/Phase 2NCT06907511Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic...Sanofi · Pandemic Influenza ImmunizationActive, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2026Sponsor estimatePhase 2NCT06958536A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's DiseaseSanofi · Crohn's DiseaseRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2026Sponsor estimatePhase 2NCT06975722A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative ColitisSanofi · Ulcerative ColitisActive, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2026Sponsor estimatePhase 2NCT06500702A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary...Sanofi · Focal Segmental GlomerulosclerosisRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06258057Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During PregnancySanofi · Pertussis (Whooping Cough)Active, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 7, 2027Sponsor estimatePhase 3NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi · Sickle Cell DiseaseRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 15, 2027Sponsor estimatePhase 3NCT04644575Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia ABioverativ, a Sanofi company · Hemophilia AActive, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 18, 2027Sponsor estimatePhase 1/Phase 2NCT06686654Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based...Sanofi Pasteur, a Sanofi Company · Human Metapneumovirus ImmunizationActive, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2027Sponsor estimatePhase 1/Phase 2NCT05584670A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsSanofi · Solid TumorRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 26, 2027Sponsor estimatePhase 1NCT07726914Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsSanofi · Chronic Graft Versus Host DiseaseNot yet recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
- Primary completion Feb 7, 2027Sponsor estimatePhase 4NCT07905547A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic DermatitisSanofi · Atopic DermatitisNot yet recruitingSNYLeadREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 9, 2027Sponsor estimatePhase 2NCT07170917Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaSanofi · Hidradenitis SuppurativaRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 11, 2027Sponsor estimatePhase 2NCT06984627A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' DiseaseSanofi · Graves' DiseaseRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 17, 2027Sponsor estimatePhase 3NCT07424144An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled...Sanofi · Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingSNYLeadREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 19 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.